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| INTRODUC TI ON
Multiple sclerosis (MS) is a heterogeneous disease with a variable clinical course. Much research has been focused on biomarkers that could predict patients' clinical course and long-term disability.
Study of the visual pathway has been a field of interest as it may reflect brain changes that contribute to patient disability (Costello, 2013) .
The retina and the optic nerve are functionally eloquent structures, known to be important targets of the disease even in patients without optic neuritis (ON) . Their study may portray brain axonal damage, with the advantage of being easily accessible by inexpensive and noninvasive techniques such as optical coherence tomography (OCT), visual evoked potentials (VEP), and transorbital sonography (TOS) of the retrobulbar optic nerve. The aim of the study was to evaluate the suitability of these three techniques to monitor visual pathway changes over a 3-year period in MS patients and to explore their relationship with disability.
| PATIENTS AND ME THODS
This was a prospective, 36-month observational study of a total of 112 eyes from 56 patients with MS, of which 29 had history and 27 did not have a history of ON. Patients were recruited from the MS clinic in the Neurology Service at Hospital General Universitario de Valencia. Eyes of patients were segregated into two cohorts according to the history of optic neuritis (hON eye cohort, n = 29) or non-history of ON (nhON eye cohort, n = 83).
All eyes underwent VEP, OCT, and TOS measurements at baseline and at 36 months. Correlation between these findings and clinical variables was explored. At the beginning of the study, baseline measurements were also compared to a healthy group.
To ensure comparability of the cohorts, baseline demographic and clinical variables of the patients were collected and compared before eye segregation. These included disease duration, accumulated number of relapses, baseline neurological disability as measured by the EDSS, baseline MRI T2 lesion and T1 Gd-enhancing lesion count, and the presence of disease-modifying treatment (Table 1) .
| Patients
We included patients younger than 50 years with relapsing-remitting MS (RRMS) diagnosis according to the 2005 McDonald criteria (Polman et al., 2005) with a score on the Expanded Disability Status Scale (EDSS) of less than or equal to 4. Measurements were taken at least 6 months after last ON episode. Patients with causes of vision loss or retinal damage not attributable to MS were excluded ( Figure 1 ).
Among the hON cohort, recordings were taken at least 6 months after the onset of ON symptoms. ON was diagnosed by the clinical criteria of ocular pain with eye movements and a decrease in visual acuity referred by the patient and confirmed in the ophthalmological examination. During the acute phase of ON, all the patients received 1 g of intravenous methylprednisolone for 3-5 days.
The study was completed ensuring compliance with current ethical and legal standard (Declaration of Helsinki) and approved by the local ethics and research committee. All the participants signed their informed consent prior to inclusion in the study. 
| Instrumental variables measured

| Technique
| Visual evoked potentials
| Transorbital ultrasound
Transorbital ultrasound (TOS) measurements of the retrobulbar optic nerve were taken with a color duplex ultrasound with a 10 Hz linear probe (Esaote MyLab™ 25 Gold). To measure the LD, the transducer was placed on the upper eyelid and the measurement was taken 3 mm from the papilla; to measure the TD, the probe was placed on the lower eyelid, perpendicular to the facial plane.
| OCT
RNFL-thick was measured by a spectral domain OCT (SD 3D OCT 2000 Top Con) with a 3D acquisition protocol (6.0 × 6.0 mm-512 × 128). Patients were scanned under photopic conditions with ceiling lights and without pupil dilation. An experienced grader masked for clinical presentation checked all images for sufficient image quality in line with the OSCAR-IB criteria (Schippling et al., 2015) and manually corrected segmentation in case of errors. All scans were carefully checked by an ophthalmologist.
| Statistics
Patients who met the inclusion criteria were consecutively recruited. 
| RE SULTS
| Baseline
The baseline clinical and demographic characteristics of the three groups are summarized in Baseline measurements (Table 2) revealed that hON eyes had statistically significant longer VEP-lat (p = .0009) and smaller RNFL-thick F I G U R E 1 Outline of the study population (p = .0012), but also a tendency for lower VEP-amp (p = .0484), LD (p = .0242), and TD values (p = .0213) with respect to nhON eyes.
A similar pattern was found when comparing nhON cohort to healthy controls, although only the decrease in RNFL-thick was found significant (p = .0036). In addition, baseline EDSS was the only clinical variable that correlated negatively with baseline RNFL-thick in the nhON cohort (r = −.4161, p = .02).
| Diagnostic performance of OCT, VEP, and TOS
To evaluate the ability of OCT, VEP, and TOS to discriminate between nhON from controls (and thus, the capability of detecting subclinical damage), we carried out a receiver operating characteristic (ROC) analysis for each test (Figure 1) . 
| Comparison of baseline and 36-month followup measurements
During follow-up, five patients with a history of ON and two patients without a history of ON were lost, resulting in a loss of five eyes in the hON and nine in the hON cohort. No patient presented an episode of ON between the two examinations. After follow-up, the groups remained homogeneous in terms of demographic and clinical variables. Final EDSS was 2.12 ± 1.25 and 1.98 ± 0.92 (p = .364), and the number of relapses was 4.08 ± 2.06 and 4.44 ± 1.75 (p = .493) in the group of patients without history and with a history of ON, respectively.
Values of repeated follow-up measurements are represented in Table 2 . Statistical significance of follow-up values with respect to baseline is shown in Table 3 .
1. In the nhON cohort, there was a statistically significant elongation in the VEP-lat and a statistically significant decrease in the VEP-amp, RFNL thickness (both globally and by quadrants), LD, and TD (VEP-lat, p = .027; VEP-amp, p = .021; RNFL-thick, 2. In the hON cohort, there was a statistically significant decrease in RNFL thickness (both globally and by quadrants), LD, and TD (RNFL-thick, p = <.001; T-RNFL-thick, p = <.001; S-RNFL-thick, p = .03; I-RNFL-thick, p = .01; N-RNFL-thick, p = <.001; LD, p = .028; TD, p = .002).
| D ISCUSS I ON
In our series, VEP, OCT, and TOS discriminated MS patients with ON from those without it, suggesting that these techniques are sensitive enough to detect structural and/or functional changes produced in the optic nerve after an acute ON episode. However, of the three techniques, OCT yielded the best performance and was the only that could discriminate between MS eyes without a history of ON (nhON group) and healthy controls, as depicted by the ROC curve Thus, our work provides further the evidence that OCT measurements could act as a marker for global axonal damage in visually asymptomatic MS patients (Alonso, Gonzalez-Moron, & Garcea, 2018) . Moreover, this was reinforced by the fact that RNFL thickness measurement by OCT correlated with EDSS at baseline.
Our data also confirm recent studies that TOS demonstrates optic nerve atrophy regardless of the presence of prior ON (Candeliere Merlicco et al., 2018; Pérez Sánchez, 2018) . However, this was the least sensitive of the three techniques to detect MS patients from Alteration of VEPs in patients without a history of ON may be useful as a supporting criterion in the diagnosis of MS because these changes may indicate subclinical damage in the visual pathway. Additionally, the functional deterioration we observed at the 3-year follow-up suggests that there is progressive functional damage to this pathway, even when visually asymptomatic. To corroborate these data and obtain more robust results, further studies with extended follow-up periods and/or a larger sample size would be desirable. Also, the use of multifocal VEPs with higher sensitivity and specificity would be very useful in detecting these visual pathway abnormalities (Klistorner et al., 2008; Laron et al., 2009) .
Given the data above, we conclude that OCT, VEP, and TOS may be valid to monitor visual pathway damage in MS patients and that OCT is the most sensitive and specific when compared to the other two. Considering the hypothesis that axonal loss is the predominant cause of disability in MS, it is predicted that RNFL thickness should be smaller in the progressive subtypes of the disease, which has already been shown by several authors (Alonso et al., 2018; Balk et al., 2016; Henderson et al., 2008; Pulicken et al., 2007; Ratchford et al., 2013) . Interestingly, the rate of RNFL thinning has been found to be greater in active and earlier phases of the disease, which could reflect a plateau effect of advanced stages (Klistorner et al., 2008; Laron et al., 2009) . Future studies intending to use any of these techniques as a measure of disability should be aware of eyes previously affected by an episode of ON, since baseline measurements could be already affected and thus, not reflect the overall axonal damage present. In our series, despite progressive damage to the optic nerve, no correlations were found between final EDSS and any of the parameters studied during follow-up. Therefore, we cannot conclude that increased axonal damage corresponds to a higher disability. Similarly, other authors were also unable to demonstrate this association (Henderson et al., 2008; Oreja-Guevara, Noval, Manzano, & Diez-Tejedor, 2010) , although recent studies established a relationship between RNFL thickness and risk of disability progression (Martínez-Lapiscina et al., 2016) , and rate of RNFL thinning and NEDA-3 at 2 years (AUC = 0.8) (Pisa et al., 2017) There may be multiple reasons for this, including the short follow-up period, patient heterogeneity, the small sample sizes used in most studies, or perhaps because EDSS is not sensitive enough to detect changes in disability when there is no motor impairment. Therefore, future studies should aim to use larger sample sizes, longer follow-up times, and more sensitive scales capable of detecting subtler changes in disability.
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